article thumbnail

EV ICD Global Pivotal Trial Results Demonstrate High ATP Success, Effective Defibrillation

DAIC

2, 2024 – Medtronic recently shared long-term results from the global Extravascular Implantable Cardioverter Defibrillator (EV ICD) Pivotal Trial, reinforcing the performance and safety of the EV-ICD system. tim.hodson Thu, 09/05/2024 - 16:02 Sept.

article thumbnail

Fifteen years of subcutaneous implantable cardioverter-defibrillator therapy: Where do we stand, and what will the future hold?

HeartRhythm

The subcutaneous implantable cardioverter-defibrillator (S-ICD) has emerged as a feasible alternative for the transvenous ICD in the treatment of ventricular tachyarrhythmias in patients without pacing or cardiac resynchronization therapy indications.

article thumbnail

Volunteer responder systems significantly increase the proportion of bystander CPR and defibrillation.

Heart 2023 Conference

Using automated external defibrillators (AEDs) and cardiopulmonary resuscitation (CPR) as soon as possible increases a person's chance of surviving a cardiac arrest. All three outcomes had higher rates across all of the included sites in the alerted cases than in the non-alerted cases: CPR on the spot: Bystander defibrillation: 73.8%

article thumbnail

Injectable hydrogel electrodes open door to a novel painless treatment regimen for arrhythmia

Science Daily - Heart Disease

Such innovation in painless defibrillation and preventing arrhythmia could revolutionize cardiac rhythm management. The scientific advance is significant considering pain management is highly relevant to overall wellness for patients with heart, lung, and blood diseases.

article thumbnail

PO-03-176 FEASIBILITY OF LEFT BUNDLE BRANCH AREA DEFIBRILLATOR IMPLANTATION USING TRADITIONAL HIGH VOLTAGE LEADS

HeartRhythm

Left bundle branch area (LBBA) pacing is an innovative cardiac pacing technique, providing physiological stimulation, useful in patients affected by atrioventricular block, and rising as an effective alternative strategy to traditional cardiac resynchronization therapy.

article thumbnail

BS-469619-002 PHARMACOLOGIC RESCUE OF LOSS-OF-FUNCTION SCN5A CHANNELOPATHY

HeartRhythm

Because there is no disease-modifying therapeutic to date, the mainstay treatment remains the implantable cardioverter defibrillator, which is associated with significant adverse events.

article thumbnail

American Heart Association Announces New 2024-2025 National Volunteer Leaders

DAIC

I am excited as the organization moves into our second century and to embrace new and innovative strategies to expand our research and understanding of how we can ensure cardiovascular health and total health for all.” in Pittsburgh. During our second century we will continue to make health equity a priority across the globe.